UroGen Pharma Doses First Patient In Phase 3 Trial Of UGN-103 For Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer, Featuring Improved Manufacturing And Reconstitution Process
UroGen Pharma Doses First Patient In Phase 3 Trial Of UGN-103 For Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer, Featuring Improved Manufacturing And Reconstitution Process
UroGen Pharma在半導體低級中危膀胱癌Phase 3試驗中首次爲UGN-103患者注射，該過程採用了改進的製造和重組過程
UroGen Pharma Doses First Patient In Phase 3 Trial Of UGN-103 For Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer, Featuring Improved Manufacturing And Reconstitution Process
UroGen Pharma在半導體低級中危膀胱癌Phase 3試驗中首次爲UGN-103患者注射，該過程採用了改進的製造和重組過程
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
資訊熱榜
更新時間